Yabao Pharmaceutical's Subsidiary Receives Approval for Ezetimibe Tablets 10mg on May 22

GateNews
According to a company announcement on May 22, Yabao Pharmaceutical's wholly-owned subsidiary Beijing Yabao Biopharmaceutical received an approval certificate from China's National Medical Products Administration for ezetimibe tablets (10mg). The drug, classified as a chemical drug category 4, is primarily used to treat primary hypercholesterolemia. The approval expands the company's portfolio of formulated products and is expected to enhance product competitiveness in the market.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments